Asthma (mild to moderate -
Conditions
Interventions
A group of randomly selected patients 12 years of age or younger (51 in total) suffering mild to moderate asthma who were under standard treatment of asthma (based on GINA algorithms) in pediatric
Treatment,Treatment
synbiotics (Kidilact ),Control
Sponsors
Shahid Beheshti University of Medical Sciences
National Research Institute of Tuberculosis and Lung Disease (Iran),Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 12 Years
Inclusion criteria
Inclusion criteria: Mild to moderate asthma
Exclusion criteria
Exclusion criteria: 1-Any other major health issues or use of any treatment or therapy that might affect trials outcomes/results. 2-Those who could not commit to the protocol or unwilling to participate anymore 3-Medication side effects 4-Loss of contact
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| synbiotic compound Kidilact® generally alleviates the symptoms of asthma in children of 12 years. 6 months after enrollment Questionnaire (times patient used rescue medications/ outpatient visits / hospital admissions ) | — |
Secondary
| Measure | Time frame |
|---|---|
| drug side effects During the research (at least 6 months) Questioner | — |
Countries
Iran
Contacts
Public ContactKeyvan Mostashari
Clinical fellow of pediatric pulmonology at Shahid Beheshti University of medical Sciences
Outcome results
None listed